摘要
本综述梳理了卡格列净在改善心脏外科手术相关心功能不全方面的研究进展。多项动物与临床研究结果显示,卡格列净可通过调节代谢、改善血流动力学、抑制炎症及纤维化等多途径机制缓解心力衰竭症状,降低不良心血管事件风险。尽管现有研究样本量较小、随访时间有限,初步证据已提示其在术后心力衰竭管理中的潜力。未来需开展更大规模、长期随访的临床试验,明确其疗效、安全性及围手术期用药策略,以指导个体化治疗。
This review summarizes current findings on the role of canagliflozin in improving cardiac insufficiency associated with cardiac surgery.Multiple animal and clinical studies have shown that canagliflozin can alleviate heart failure symptoms and reduce the risk of adverse cardiovascular events through multiple mechanisms such as regulating metabolism,improving hemodynamics,inhibiting inflammation and fibrosis.Despite limitations in sample size and follow-up duration,preliminary data support its therapeutic potential in postoperative care.In the future,larger scale and long-term follow-up clinical trials are needed to clarify their efficacy,safety and perioperative medication strategies,in order to guide individualized treatment.
作者
董宇梁
周帆
迟立群
穆军升
DONG Yuliang;ZHOU Fan;CHI Liqun;MU Junsheng(Capital Medical University,Beijing 100069,China;Department of Ultrasound,The Third Medical Center of People’s Liberation Army of China General Hospital,Beijing 100039,China;Department of Cardiac Surgery,Beijing Anzhen Hospital,Capital Medical University,Beijing Institute of Heart Lung and Blood Vessel Diseases,Beijing 100029,China;Department of Cardiac Surgery,The Third Affiliated Hospital of Xinxiang Medical University,Xinxiang 453000,Henan,China)
出处
《心血管病学进展》
2025年第9期778-781,共4页
Advances in Cardiovascular Diseases
基金
国家自然科学基金(82270255)
2025年首都医科大学学生科研创新项目(XSKY2025248)。
